entacapone

BIPARK-1 was a Phase III, randomised, double-blind placebo- and active-controlled study of opicapone as an adjunct to levodopa therapy in which 600 patients with Parkinson's disease and motor fluctuations received once-daily opicapone (5 mg, 25 mg, or 50 mg), placebo, or 200 mg doses of the COMT inhibitor entacapone for 14 to 15 weeks.

Potential of microemulsified entacapone drug delivery systems in the management of acute Parkinson's disease.

of Clarithromycin Extended Release Tablets 500 mg and Entacapone Immediate Release tablets 200 mg.

Dosage reduction, monotherapy, or discontinuation in these patients could be helpful and could be replaced by selegiline, amantadine, or entacapone, which have no effects on EDS [45],[52] and may even reduce or resolve EDS.[4],[28],[52],[53],[54] Although clonazepam is the mainstay of treatment for RBD, given its associated risks, benzodiazepine use should generally be avoided in PD patients with EDS.

(1,20) In general, these complications are managed by the addition of a dopamine agonist, MAO-B inhibitor, or a catechol-O-methyltransferase (COMT) inhibitor (entacapone).

levodopa+benserazide, pramipexole (B) levodopa+benserazide, Dysphagia, pramipexole, sleep disorders, entacapone and depression clonazepam, zolpidem escitalopram Others (2) (C) levodopa+benserazide, pramipexole Sleep disorders Others (1) (D) Dysphagia, dysphonia, perspiration, levodopa+benserazide, hypotension, pramipexole urinary Others (6) incontinence and sleep disorders.

All participants were treated with levodopa, and additional antiparkinsonian therapy consisted of oral dopamine agonists (pramipexole and ropinirole), COMT inhibitors (entacapone and tolcapone), amantadine, subcutaneous apomorphine infusion, and deep brain stimulation.

His current medications include alprostadil, amantadine, carbidopa/levodopa, entacapone, loratadine, midodrine, oxybutynin, ropinirole, and simvastatin.

(46) Although lacking empirical evidence, catechol-O-methyltransferase (COMT) inhibitors, such as entacapone, have an anti-craving affect and are used by some clinicians to improve adherence with buprenorphine.